SAR443216
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SAR443216, covering 2025-09-15 to 2025-09-15. Get the full timeline:
Most recent: Clinical Trial Update: Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors [Phase 1]